/ /

  • linkedin
  • Increase Font
  • Sharebar

    Sustained-release topical rings promising for glaucoma

    Study aims to compare effectiveness, safety of rings versus eye drops

    Take-home: A single bimatoprost topical ring has been shown to be effective and safe for lowering IOP over six months, according to results from a phase II study.

    Topical rings (Bimatoprost Ring, ForSight Vision5) that release bimatoprost continually for up to six months have safely lowered IOP in a phase II clinical trial, according to researchers.

    “It was very well tolerated by the patients,” said James D. Brandt, MD, director of Glaucoma Service, UC Davis Eye Center, Sacramento, CA.

    “While patients who used the inserts had slightly less reduction in IOP than patients taking timolol eye drops, the pressure reduction was significant and the rings promise to provide substantial benefit to the many patients who have trouble taking eye drops – whether due to memory issues or the simple physical challenge of using drops correctly,” Dr. Brandt said.

    Results of the phase II study were recently published in Ophthalmology (2016;123:1685-1694) Dr. Brandt will present 19-month data at the 2016 annual meeting of the American Academy of Ophthalmology in Chicago.

    The ring is designed to address a key problem in the management of glaucoma, he said. While eye drops can effectively lower IOP, patients struggle with understanding glaucoma, remembering to take the eye drops on a regular schedule, and often lack the physical dexterity to apply the eye drops correctly. As a result, patients often do not administer the drops as often as they are needed. Recent literature has shown only 15% of patients remain consistently adherent to their glaucoma eye drops over a 4-year period.1

    Solving adherence problems

    New Call-to-action

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Poll

    View Results